{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Louisville&page=18&state=Kentucky", "query": { "state": "Kentucky", "city": "Louisville", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 1174, "total_pages": 118, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Louisville&page=19&state=Kentucky&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Louisville&page=17&state=Kentucky&page_size=10" }, "source": "local", "last_synced_at": "2026-10-20T13:15:38.543Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05102019", "title": "Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Refractory Angina" ], "interventions": [ { "name": "Arm 1: treatment with Shockwave Reducer", "type": "DEVICE" }, { "name": "Arm 2 (control): Implantation procedure with no device implanted", "type": "OTHER" }, { "name": "Arm 3 (unblinded, non-randomized): Single arm registry", "type": "DEVICE" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Shockwave Medical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2022-01-04", "completion_date": "2032-01", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-15T18:47:18.406Z", "location_count": 72, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05102019" }, { "nct_id": "NCT07391657", "title": "A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Refractory Multiple Myeloma" ], "interventions": [ { "name": "AZD0120", "type": "BIOLOGICAL" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 508, "start_date": "2026-02-23", "completion_date": "2030-07-29", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-14T10:31:39.862Z", "location_count": 48, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07391657" }, { "nct_id": "NCT07265674", "title": "A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Biliary Tract Cancer", "Biliary Tract Cancer (BTC)" ], "interventions": [ { "name": "Nanvuranlat", "type": "DRUG" }, { "name": "Physician's Best Choice", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "J-Pharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": "2026-05-11", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-14T03:52:20.186Z", "location_count": 18, "location_summary": "Duarte, California • Orange, California • Santa Monica, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07265674" }, { "nct_id": "NCT07224425", "title": "A Study of BI 3810944 in Patients With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Solid Tumours" ], "interventions": [ { "name": "BI 3810944", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2026-02-24", "completion_date": "2029-10-05", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-15T17:19:40.522Z", "location_count": 4, "location_summary": "Louisville, Kentucky • Nashville, Tennessee • Houston, Texas + 1 more", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224425" }, { "nct_id": "NCT07011719", "title": "Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Casdatifan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 720, "start_date": "2025-09-08", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-20T13:15:38.543Z", "location_count": 46, "location_summary": "Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 40 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07011719" }, { "nct_id": "NCT06619990", "title": "Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ulcerative Colitis (UC)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "XmAb942", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 270, "start_date": "2024-10-10", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-15T03:53:27.024Z", "location_count": 30, "location_summary": "Scottsdale, Arizona • Palo Alto, California • Bradenton, Florida + 25 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Brandon", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06619990" }, { "nct_id": "NCT06237452", "title": "VE303 for Prevention of Recurrent Clostridioides Difficile Infection", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "C. Diff Infection", "C.Difficile Diarrhea", "CDI", "Clostridioides Difficile Infection", "Clostridioides Difficile Infection Recurrence", "Clostridium Difficile", "Clostridium Difficile Infection Recurrence", "Clostridium Difficile Infections", "Diarrhea Infectious", "Recurrent Clostridium Difficile Infection" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "VE303", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vedanta Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 852, "start_date": "2024-05-20", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-15T12:07:12.816Z", "location_count": 84, "location_summary": "Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Apple Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06237452" }, { "nct_id": "NCT05128825", "title": "A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer" ], "interventions": [ { "name": "azenosertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 310, "start_date": "2022-02-17", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-08T21:47:12.952Z", "location_count": 43, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05128825" }, { "nct_id": "NCT07221253", "title": "A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Biliary Tract Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Gemcitabine/Cisplatin", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1100, "start_date": "2025-12-04", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-14T01:07:57.574Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221253" }, { "nct_id": "NCT07089888", "title": "A Study of Dotinurad Versus Allopurinol in Tophaceous Gout", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tophaceous Gout" ], "interventions": [ { "name": "Allopurinol", "type": "DRUG" }, { "name": "Dotinurad", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crystalys Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 250, "start_date": "2025-08-04", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-05T00:00:09.230Z", "location_count": 95, "location_summary": "Birmingham, Alabama • Foley, Alabama • Gilbert, Arizona + 85 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Foley", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07089888" } ] }